UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 157

Sortiert nach

Revised catalogue of earthquake mechanisms for the events occurred in Romania until the end of twentieth century: REFMC

Acta geodaetica et geophysica, 2019-03, Vol.54 (1), p.3-18

2019

Volltextzugriff (PDF)

Probabilistic seismic hazard map for Romania as a basis for a new building code

Natural hazards and earth system sciences, 2005-01, Vol.5 (5), p.679-684

2005

Volltextzugriff (PDF)

Probabilistic seismic hazard in terms of intensities for Bulgaria and Romania – updated hazard maps

Natural hazards and earth system sciences, 2008-01, Vol.8 (6), p.1431-1439

2008

Volltextzugriff (PDF)

Effects of the seismic attenuation pattern at the bend of the Southeastern Carpathians on the peak ground motions from local crustal earthquakes

Romanian reports in physics, 2024-09, Vol.76 (2), p.707-707

2024

Volltextzugriff (PDF)

Statistical models of the seismicity of the Vrancea region, Romania: Special Issue on Seismicity Patterns. Earthquake Parameters

Natural hazards (Dordrecht), 1999, Vol.19 (2-3), p.151-164

ARDELEANU, L

1999

Volltextzugriff (PDF)

Source parameters of weak crustal earthquakes of the Vrancea region from short-period waveform inversion

Pure and applied geophysics, 2005-03, Vol.162 (3), p.495-513

2005

Volltextzugriff (PDF)

Statistical Models of the Seismicity of the Vrancea Region, Romania

Natural hazards (Dordrecht), 1999-05, Vol.19 (2-3), p.151-164

Ardeleanu, Luminia

1999

Volltextzugriff (PDF)

MLH1, BRAF and p53 - searching for significant markers to predict evolution towards adenocarcinoma in colonic sessile serrated lesions

Romanian journal of morphology and embryology, 2021-10, Vol.62 (4), p.971-979

2021

Volltextzugriff (PDF)

Waveform inversion of weak vrancea (Romania) earthquakes

Studia geophysica et geodaetica, 1996-10, Vol.40 (4), p.367-380

1996

Volltextzugriff (PDF)

Amplitude domain analysis for the 30 August 1986 Vrancea intermediate earthquake

Natural hazards (Dordrecht), 1990, Vol.3 (3), p.305-314

1990

Volltextzugriff (PDF)

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

The New England journal of medicine, 2016-12, Vol.375 (24), p.2335-2348

2016

Volltextzugriff (PDF)

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.761-769

2019

Volltextzugriff (PDF)

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

Journal of the American Academy of Dermatology, 2016-03, Vol.74 (3), p.491-498

2016

Volltextzugriff (PDF)

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

British journal of dermatology (1951), 2020-05, Vol.182 (5), p.1120-1135

2020

Volltextzugriff (PDF)

Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

Journal of dermatological science, 2019-05, Vol.94 (2), p.266-275

2019

Volltextzugriff (PDF)

Conjunctivitis in dupilumab clinical trials

British journal of dermatology (1951), 2019-09, Vol.181 (3), p.459-473

2019

Volltextzugriff (PDF)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

British journal of dermatology (1951), 2020-01, Vol.182 (1), p.85-96

2020

Volltextzugriff (PDF)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

American journal of clinical dermatology, 2019-06, Vol.20 (3), p.443-456

2019

Volltextzugriff (PDF)

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology, 2016-09, Vol.75 (3), p.506-515

2016

Volltextzugriff (PDF)

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

British journal of dermatology (1951), 2019-07, Vol.181 (1), p.80-87

2019

Volltextzugriff (PDF)

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

The Journal of dermatological treatment, 2020-08, Vol.31 (6), p.606-614

2020

Volltextzugriff (PDF)

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

The New England journal of medicine, 2017-03, Vol.376 (11), p.1090-1091

2017

Volltextzugriff (PDF)

Short report on navigating access to care for Medicaid-enrolled autistic youth and young adults: Examining accrual of intellectual disability diagnoses in adolescence

Autism : the international journal of research and practice, 2024-03, Vol.28 (3), p.780-785

2024

Volltextzugriff (PDF)

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis

Journal of investigative dermatology, 2020-01, Vol.140 (1), p.191-202.e7

2020

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Revised catalogue of earthquake mechanisms for the events occurred in Romania until the end of twentieth century: REFMC

Probabilistic seismic hazard map for Romania as a basis for a new building code

Probabilistic seismic hazard in terms of intensities for Bulgaria and Romania – updated hazard maps

Effects of the seismic attenuation pattern at the bend of the Southeastern Carpathians on the peak ground motions from local crustal earthquakes

Statistical models of the seismicity of the Vrancea region, Romania: Special Issue on Seismicity Patterns. Earthquake Parameters

Source parameters of weak crustal earthquakes of the Vrancea region from short-period waveform inversion

Statistical Models of the Seismicity of the Vrancea Region, Romania

MLH1, BRAF and p53 - searching for significant markers to predict evolution towards adenocarcinoma in colonic sessile serrated lesions

Waveform inversion of weak vrancea (Romania) earthquakes

Amplitude domain analysis for the 30 August 1986 Vrancea intermediate earthquake

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

Conjunctivitis in dupilumab clinical trials

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Short report on navigating access to care for Medicaid-enrolled autistic youth and young adults: Examining accrual of intellectual disability diagnoses in adolescence

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis

Suchergebnisse filtern